ERAS Erasca, Inc.
ERAS Erasca, Inc.
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 2 scans as of 2026-10-23 2 neutral converging
POC $14.58 · VWAP $13.09 · +10.0% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
1 watchlist
ERAS Price Structure
Loading timeframes…
Peers
Every watchlist ERAS belongs to, members best 30-day change first — ERAS highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported the quarter ending 2026-06-30: diluted EPS -$0.14, net income -$44M (SEC filing). Across the print the stock moved -2.5% (close before → first close after).
full note →Against street estimates
How ERAS's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
Recent news
Headlines about ERAS from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 1 day ago · Oct 22
- Erasca, Inc. (ERAS) stock price, news, quote and history - Yahoo Finance
- Erasca, Inc. Common Stock (ERAS) Stock Price & Analysis | Bamboo
- Erasca, Inc. (ERAS) Latest Stock News & Headlines - Yahoo Finance
- Erasca Reports Second Quarter 2026 Business Updates and Financial Results - BioSpace
- Erasca Reports First Quarter 2026 Business Updates and Financial Results | Nasdaq
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
ERAS research tape
86 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.